Research programme: monoclonal antibody HUI 77-derived cancer therapies - Micromet

Drug Profile

Research programme: monoclonal antibody HUI 77-derived cancer therapies - Micromet

Alternative Names: QH2B

Latest Information Update: 18 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Southern California
  • Developer Micromet Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Collagen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Eye-Disorders; Solid tumours

Most Recent Events

  • 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
  • 03 Apr 2006 The US FDA has approved an IND application for D93 to begin phase I trials in solid tumours
  • 25 Jul 2005 Preclinical trials in Eye disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top